{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:32:35Z","timestamp":1793514755760,"version":"4.5.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-IgLON5 disease is a relatively new neurological entity with the first cases reported in 2014. So far, less than 70 articles on this topic have been published. Due to its unspecific symptomatology, diverse progression, novelty and ambiguous character, it remains a difficulty for both clinical practitioners and scientists. The aim of this review is to summarize the current knowledge concerning anti-IgLON5 disease; mechanisms underlying its cause, symptomatology, clinical progression, differential diagnosis and treatment, which could be helpful in clinical practice and future research.<\/jats:p>","DOI":"10.3389\/fimmu.2022.852215","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:05:46Z","timestamp":1646121946000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["Anti-IgLON5 Disease \u2013 The Current State of Knowledge and Further Perspectives"],"prefix":"10.3389","volume":"13","author":[{"given":"Natalia","family":"Madetko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Marzec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Przewodowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Alster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Koziorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003887","article-title":"Clinical Manifestations of the Anti-IgLON5 Disease","volume":"88","author":"Gaig","year":"2017","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00038","article-title":"Promoter-Specific Expression and Genomic Structure of IgLON Family Genes in Mouse","volume":"11","author":"Vanaveski","year":"2017","journal-title":"Front Neurosci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1212\/NXI.0000000000000385","article-title":"IgLON5 Antibody: Neurological Accompaniments and Outcomes in 20 Patients","volume":"4","author":"Honorat","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2004.04002.x","article-title":"Differential Neural Control of Glomerular Ultrafiltration","volume":"31","author":"Denton","year":"2004","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.29245\/2572.942X\/2020\/3.1269","article-title":"Anti-Iglon5 Syndrome: What We Know So Far? A Non-Systematic Review","volume":"5","author":"da Silva","year":"2020","journal-title":"J Neurol Neuromed"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e962","DOI":"10.1212\/NXI.0000000000000962","article-title":"Anti-IgLON5 Disease: A New Bulbar-Onset Motor Neuron Mimic Syndrome","volume":"8","author":"Werner","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70051-1","article-title":"A Novel non-Rapid-Eye Movement and Rapid-Eye-Movement Parasomnia With Sleep Breathing Disorder Associated With Antibodies to IgLON5: A Case Series, Characterisation of the Antigen, and Post-Mortem Study","volume":"13","author":"Sabater","year":"2014","journal-title":"Lancet Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/1176934318775081","article-title":"Molecular Evolution and Functional Divergence of the IgLON Family","volume":"14","author":"Kubick","year":"2018","journal-title":"Evol Bioinform Online"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00008","article-title":"Altered Expression Profile of IgLON Family of Neural Cell Adhesion Molecules in the Dorsolateral Prefrontal Cortex of Schizophrenic Patients","volume":"11","author":"Karis","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.1600","article-title":"IgLON Cell Adhesion Molecules Regulate Synaptogenesis in Hippocampal Neurons","volume":"27","author":"Hashimoto","year":"2009","journal-title":"Cell Biochem Funct"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1591-8","article-title":"Neuropathological Criteria of Anti-IgLON5-Related Tauopathy","volume":"132","author":"Gelpi","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170259","article-title":"Expanding the Clinical Spectrum of IgLON5-Syndrome","volume":"4","author":"Wenninger","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11940-018-0515-4","article-title":"Anti-IgLON 5 Disease","volume":"20","author":"Heidbreder","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12883-021-02145-4","article-title":"Improvement in Mild Anti-IgLON5 Encephalopathy Without Immunotherapy: A Case Report","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a9585f","article-title":"Encephalitis and GABAB Receptor Antibodies: Novel Findings in a New Case Series of 20 Patients","volume":"81","author":"H\u00f6ftberger","year":"2013","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","article-title":"Antibodies to the GABA(B) Receptor in Limbic Encephalitis With Seizures: Case Series and Characterisation of the Antigen","volume":"9","author":"Lancaster","year":"2010","journal-title":"Lancet Neurol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/cells10040837","article-title":"Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons","volume":"10","author":"Ryding","year":"2021","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.07.010","article-title":"An Autopsy Case of MM2-Thalamic Subtype of Sporadic Creutzfeldt-Jakob Disease With Lewy Bodies Presenting as a Sleep Disorder Mimicking Anti-IgLON5 Disease","author":"Hongo","year":"2019","journal-title":"J Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14634","article-title":"Altered Ioflupane Single-Photon Emission Computed Tomography in Anti-IgLON5 Disease: A New Case Mimicking Probable Progressive Supranuclear Palsy and Review of the Literature","volume":"28","author":"Gonz\u00e1lez-\u00c1vila","year":"2021","journal-title":"Eur J Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26987","article-title":"Movement Disorder Society-Endorsed PSP Study Group. Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14308","article-title":"Anti-IGLON5-Syndrom Presenting Fasciculations and Oculomotor Palsy Associated With Renal Neoplasia","author":"Rauf","year":"2020","journal-title":"Eur J Of Neurol. SUPnan"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2388","article-title":"The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates","volume":"11","author":"Ntougkos","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B23","unstructured":""},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.07.008","article-title":"Anti-IgLON5 Disease in a Pediatric Patient With Langerhans Cell Histiocytosis","volume":"521","author":"Ye","year":"2021","journal-title":"Clin Chim Acta"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020417","article-title":"IgLON5 Regulates the Adhesion and Differentiation of Myoblasts","volume":"10","author":"Lim","year":"2021","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/nyas.12553","article-title":"Autoimmune Encephalopathies","volume":"1338","author":"Leypoldt","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12974-016-0689-1","article-title":"Cellular Investigations With Human Antibodies Associated With the Anti-IgLON5 Syndrome","volume":"13","author":"Sabater","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01056","article-title":"Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature","volume":"10","author":"Nissen","year":"2019","journal-title":"Front Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00576","article-title":"Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis","volume":"11","author":"Hansen","year":"2020","journal-title":"Front Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1212\/NXI.0000000000000651","article-title":"Anti-IGLON5 Disease: A New Case Without Neuropathologic Evidence of Brainstem Tauopathy","volume":"7","author":"Erro","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13016","article-title":"Unusual Head Movements in Anti-IgLON5 Disease","volume":"7","author":"Peeters","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26608","article-title":"Dystonia, Lower Limb Stiffness, and Upward Gaze Palsy in a Patient With IgLON5 Antibodies","volume":"31","author":"Br\u00fcggemann","year":"2016","journal-title":"Mov Disord"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012639","article-title":"Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease","volume":"97","author":"Gaig","year":"2021","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0463-z","article-title":"Sleep and Neurological Autoimmune Diseases","volume":"45","author":"Iranzo","year":"2020","journal-title":"Neuropsychopharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000677","article-title":"Neurological Profiles Beyond the Sleep Disorder in Patients With Anti-IgLON5 Disease","volume":"32","author":"Gaig","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13038","article-title":"Motor Neuron Disease-Like Phenotype Associated With Anti-IgLON5 Disease","volume":"24","author":"Tao","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101515","article-title":"REM Sleep Behavior Disorder: Mimics and Variants","volume":"60","author":"Antelmi","year":"2021","journal-title":"Sleep Med Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz133","article-title":"Characterization of the Sleep Disorder of Anti-IgLON5 Disease","volume":"42","author":"Gaig","year":"2019","journal-title":"Sleep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11910-018-0848-0","article-title":"The Sleep Disorder in Anti-Lglon5 Disease","volume":"18","author":"Gaig","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10386-5","article-title":"Bilateral Vestibulopathy in Anti-IgLON5 Disease","volume":"268","author":"Helmchen","year":"2021","journal-title":"J Neurol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1212\/NXI.0000000000000302","article-title":"Isolated Dysphagia as Initial Sign of Anti-IgLON5 Syndrome","volume":"4","author":"Schr\u00f6der","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/lary.28911","article-title":"A Novel Presentation of the Acute Airway: Anti-IgLON5 Disease","volume":"131","author":"Chen","year":"2021","journal-title":"Laryngoscope"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.753856","article-title":"Ocular Motor Abnormalities in Anti-IgLON5 Disease","volume":"12","author":"Macher","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.632497","article-title":"Case Report: Neuropsychological Findings in IgLON5 Antibody Disorder","volume":"12","author":"El Shazly","year":"2021","journal-title":"Front Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1212\/NXI.0000000000000605","article-title":"HLA and Microtubule-Associated Protein Tau H1 Haplotype Associations in Anti-IgLON5 Disease","volume":"6","author":"Gaig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e24384","DOI":"10.1097\/MD.0000000000024384","article-title":"Anti-IgLON5 Disease With Distinctive Brain MRI Findings Responding to Immunotherapy: A Case Report","volume":"100","author":"Pi","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-2457(02)00022-6","article-title":"Agrypnia Excitata: A Generalized Overactivity Syndrome and a Useful Concept in the Neurophysiopathology of Sleep","volume":"113","author":"Montagna","year":"2002","journal-title":"Clin Neurophysiol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09924-y","article-title":"Early Immunotherapy Is Highly Effective in IgG1\/IgG4 Positive IgLON5 Disease","volume":"267","author":"Gr\u00fcter","year":"2020","journal-title":"J Neurol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1212\/NXI.0000000000000136","article-title":"Sleep Disorder, Chorea, and Dementia Associated With IgLON5 Antibodies","volume":"2","author":"Simabukuro","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09221-3","article-title":"Intravenous Immunoglobulins as First-Line Therapy for IgLON5 Encephalopathy","volume":"266","author":"Logmin","year":"2019","journal-title":"J Neurol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005679","article-title":"IgLON5-Mediated Neurodegeneration Is a Differential Diagnosis of CNS Whipple Disease","volume":"90","author":"Morales-Briceno","year":"2018","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1053\/j.gastro.2007.04.070","article-title":"Sera of Patients With Celiac Disease and Neurologic Disorders Evoke a Mitochondrial-Dependent Apoptosis In Vitro","volume":"133","author":"Cervio","year":"2007","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2005.11.013","article-title":"Anti-Ganglioside Antibodies in Coeliac Disease With Neurological Disorders","volume":"38","author":"Volta","year":"2006","journal-title":"Digestive Liver Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13223-021-00557-y","article-title":"Anti-Ganglioside Antibodies and Celiac Disease","volume":"17","author":"Granito","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15117","article-title":"Expanding the Clinical Spectrum of Anti-IgLON5 Disease: A Multicenter Retrospective Study","volume":"29","author":"Ni","year":"2021","journal-title":"Eur J Neurol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3638","article-title":"Distinctive Magnetic Resonance Imaging Findings in IgLON5 Antibody Disease","volume":"77","author":"Chen","year":"2020","journal-title":"JAMA Neurol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2016.09.012","article-title":"Chorea and Parkinsonism Associated With Autoantibodies to IgLON5 and Responsive to Immunotherapy","volume":"300","author":"Haitao","year":"2016","journal-title":"J Neuroimmunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13207","article-title":"Response to Immunotherapy in Anti-IgLON5 Disease: A Systematic Review","volume":"141","author":"Cabezudo-Garc\u00eda","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1212\/NXI.0000000000001009","article-title":"Delayed Benefit From Aggressive Immunotherapy in Waxing and Waning Anti-IgLON5 Disease","volume":"8","author":"Shambrook","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1212\/NXI.0000000000000577","article-title":"Immunotherapy Improves Sleep and Cognitive Impairment in Anti-IgLON5 Encephalopathy","volume":"6","author":"Brunetti","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1212\/NXI.0000000000001116","article-title":"IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies","volume":"9","author":"Dalakas","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(15)60445-7","article-title":"IgLON5 Autoimmunity and Abnormal Behaviours During Sleep","volume":"385","author":"H\u00f6gl","year":"2015","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030656","article-title":"Mechanisms of Neurodegeneration in Various Forms of Parkinsonism\u2014Similarities and Differences","volume":"10","author":"Koziorowski","year":"2021","journal-title":"Cells"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.852215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T08:05:48Z","timestamp":1646121948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.852215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2022.852215"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.852215","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"article-number":"852215"}}